Reply to G. Sonpavde et al

Journal of Clinical Oncology

Volumn 28, Issue 13, 2010, Pages

  Bellmunt, Joaquim ^a   Salhi, Yacine ^b  

^a HOSPITAL DEL MAR   (Spain)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VINFLUNINE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; METHODOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME;

EID: 79951763751     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.1338     Document Type: Letter

References (6)

1. Sonpavde G, Rosenberg JE, Hahn NM, et al: Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. J Clin Oncol 28:e205-e207, 2010
2. Bellmunt J, Theodore C, Demkov T, et al: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461, 2009
3. Simon GR, Turrisi A: Management of small cell lung cancer: ACCP evidencebased clinical practice guidelines (ed 2). Chest 132:324S-339S, 2007
4. Hennessy BT, Coleman RL, Markman M: Ovarian cancer. Lancet 374:1371-1382, 2009
5. Culine S, Theodore C, De Santis M, et al: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94:1395-1401, 2006 (Pubitemid 43772272)
6. Vaughn DJ, Srinivas S, Stadler WM, et al: Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study. Cancer 115:4110-4117, 2009